BR9611210A - Composições e processos para tratamento de condições ósseas deficitárias - Google Patents

Composições e processos para tratamento de condições ósseas deficitárias

Info

Publication number
BR9611210A
BR9611210A BR9611210-7A BR9611210A BR9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A
Authority
BR
Brazil
Prior art keywords
bone
compositions
processes
ability
development
Prior art date
Application number
BR9611210-7A
Other languages
English (en)
Inventor
Charles Petrie
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BR9611210A publication Critical patent/BR9611210A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES E PROCESSOS PARA TRATAMENTO DE CONDIçõES óSSEAS DEFICITáRIAS"<D>. Compostos contendo dois sistemas aromáticos covalentemente ligados através de um ligante contendo um ou mais átomos, ou "ligante" definido como incluindo uma ligação covalente por si, de modo a espaçar os sistemas aromáticos a uma distância de 1,5-15<sym> são eficazes nas condições de tratamento associados aos déficits ósseos. Os compostos podem ser administrados aos indivíduos vertebrados sozinhos ou em combinação com agentes adicionais que promovem o desenvolvimento ósseo ou que inibam a ressorção ósseas. Eles podem ser classificados por atividade antes da administração por avaliar sua capacidade de efetuar a transição de um gene repórter acoplado a um promotor associado a uma proteína morfogenética ósse e/ou sua capacidade de estimular o desenvolvimento calvarial nos sistemas animais modelos.
BR9611210-7A 1995-10-23 1996-10-23 Composições e processos para tratamento de condições ósseas deficitárias BR9611210A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
PCT/US1996/017019 WO1997015308A1 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Publications (1)

Publication Number Publication Date
BR9611210A true BR9611210A (pt) 1999-12-28

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611210-7A BR9611210A (pt) 1995-10-23 1996-10-23 Composições e processos para tratamento de condições ósseas deficitárias

Country Status (13)

Country Link
EP (1) EP0866710A4 (pt)
JP (1) JP2000513324A (pt)
KR (1) KR19990067010A (pt)
CN (1) CN1201393A (pt)
AU (1) AU706262B2 (pt)
BR (1) BR9611210A (pt)
CA (1) CA2235481A1 (pt)
CZ (1) CZ115398A3 (pt)
EA (1) EA199800393A1 (pt)
HU (1) HUP9802319A3 (pt)
NO (1) NO981810L (pt)
PL (1) PL327617A1 (pt)
WO (1) WO1997015308A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL330814A1 (en) 1996-06-20 1999-06-07 Regents Board Of Compounds for and methods of delivering pharmaceutical preparations and their application
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (de) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
JP2000004882A (ja) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
JP2003517447A (ja) * 1998-11-06 2003-05-27 ビーエーエスエフ アクチェンゲゼルシャフト 三環式ピラゾール誘導体
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (en) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
KR100641802B1 (ko) 1999-12-28 2006-11-02 에자이 가부시키가이샤 술폰아미드 함유 복소환 화합물
FR2806408B1 (fr) * 2000-03-17 2002-10-11 Oreal Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives
EP1361224B1 (de) 2000-06-05 2005-12-28 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Heterocyclische Hydrazone als anti-Krebs-Wirkstoffe
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
JPWO2003082808A1 (ja) * 2002-04-03 2005-08-04 住友製薬株式会社 ベンズアミド誘導体
US20050260126A1 (en) * 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2004054978A1 (ja) * 2002-12-16 2004-07-01 Bf Research Institute, Inc. タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
ES2389907T3 (es) 2004-04-30 2012-11-02 Takeda Pharmaceutical Company Limited Compuesto de amida heterocíclica y uso del mismo como un inhibidor de MMP-13
AR052674A1 (es) 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
EP2346837B8 (en) 2008-06-26 2015-04-15 Resverlogix Corporation Methods of preparing quinazolinone derivatives
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US8822462B2 (en) * 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
NZ708314A (en) 2009-03-18 2017-08-25 Resverlogix Corp Quinazolinones for use as anticancer agents
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
PL2773354T3 (pl) 2011-11-01 2019-12-31 Resverlogix Corp. Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów
US9388138B2 (en) 2012-07-18 2016-07-12 University College Dublin National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (zh) * 2012-10-22 2013-02-27 暨南大学 一种乙烯桥连吲哚化合物及其合成方法和用途
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
CN107019687B (zh) * 2017-05-08 2020-10-27 上海市伤骨科研究所 N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途
CN111116552B (zh) * 2020-01-17 2022-10-11 河北科技大学 一种喹唑啉酮类化合物及其制备方法
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递***的应用
CN116650495B (zh) * 2021-12-10 2024-04-19 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (ja) * 1987-12-18 1998-03-09 武田薬品工業株式会社 骨粗鬆症予防治療剤
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JPH06192272A (ja) * 1992-12-24 1994-07-12 Japan Tobacco Inc 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (en) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Malonic acid based matrix metalloproteinase inhibitors
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth

Also Published As

Publication number Publication date
EP0866710A4 (en) 2001-07-11
HUP9802319A3 (en) 1999-12-28
EA199800393A1 (ru) 1998-12-24
NO981810L (no) 1998-06-22
AU706262B2 (en) 1999-06-10
JP2000513324A (ja) 2000-10-10
WO1997015308A1 (en) 1997-05-01
NO981810D0 (no) 1998-04-22
AU7471096A (en) 1997-05-15
EP0866710A1 (en) 1998-09-30
CA2235481A1 (en) 1997-05-01
CZ115398A3 (cs) 1998-12-16
CN1201393A (zh) 1998-12-09
KR19990067010A (ko) 1999-08-16
HUP9802319A2 (hu) 1999-02-01
PL327617A1 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
BR9611210A (pt) Composições e processos para tratamento de condições ósseas deficitárias
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
BR9917082A (pt) Compostos inibidores da produção de proteìnas a&#34;beta&#34;, método de tratamento de disfunções neurológicas associadas com a produção de &#34;beta&#34;-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase
BR0206689A (pt) Combinação de probióticos, e, uso desta
BR9815159A (pt) Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
HRP20010877B1 (en) Composition for prevention and treatment of amyloidogenic disease
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
ES2109260T3 (es) Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
ES2133329T3 (es) Variantes de il-3 humana.
TR200101649T2 (tr) Piperazin türevleri.
BR9810703A (pt) Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta
TR200100637T2 (tr) Yeni doğal ürün türevleri
BR0006088A (pt) Derivados de proteìna c
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR9915071A (pt) Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law